From JANUVIA to MARIZEV (Omarigliptin), a once weekly DPP-4 inhibitor for the treatment of diabetes

被引：0
|
作者：
Weber, Ann [1 ]
机构：
[1] Kallyope Inc, New York, NY USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2018年 / 255卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
15
引用
收藏
页数：1
相关论文
共 50 条
  • [11] A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
    Ira Gantz
    Menghui Chen
    Shailaja Suryawanshi
    Catherine Ntabadde
    Sukrut Shah
    Edward A. O’Neill
    Samuel S. Engel
    Keith D. Kaufman
    Eseng Lai
    Cardiovascular Diabetology, 16
  • [12] Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Improves Glycemic Control in Patients Inadequately Controlled on the Combination of Metformin and Glimepiride
    Lee, Seung-Hwan
    Gantz, Ira
    Round, Elizabeth
    O'Neill, Edward A.
    Latham, Melanie
    Ceesay, Paulette
    Suryawanshi, Shailaja
    Lai, Eseng
    DIABETES, 2016, 65 : A50 - A50
  • [13] A Multicenter, Randomized Controlled Study of the Efficacy of Once-Weekly DPP-4 Inhibitor Omarigliptin in Patients with Type 2 Diabetes Undergoing Maintenance Hemodialysis
    Yoshizawa, Yuta
    Hosojima, Michihiro
    Kabasawa, Hideyuki
    Tanabe, Naohito
    Kitamura, Tadahiro
    Narita, Ichiei
    Saito, Akihiko
    DIABETES, 2019, 68
  • [14] The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus A systemic review and meta-analysis
    Wang, Xianying
    Li, Xuejing
    Qie, Suhui
    Zheng, Yingying
    Liu, Yang
    Liu, Guoqiang
    MEDICINE, 2018, 97 (34)
  • [15] Omarigliptin, a once-weekly DPP-4 inhibitor, provides similar glycaemic control to sitagliptin in patients with type 2 diabetes mellitus inadequately controlled on metformin
    Gantz, I.
    Lai, E.
    Suryawanshi, S.
    Andryuk, P.
    Engel, S. S.
    DIABETOLOGIA, 2015, 58 : S54 - S55
  • [16] Effect of omarigliptin, a novel once-weekly DPP-4 inhibitor, in Japanese patients with type 2 diabetes: a placebo- and sitagliptin-controlled trial
    Gantz, I.
    Okamoto, T.
    Ito, Y.
    Okuyama, K.
    Engel, S. S.
    DIABETOLOGIA, 2014, 57 : S55 - S55
  • [17] A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment
    Chacra, Antonio
    Gantz, Ira
    Mendizabal, Geraldine
    Durlach, Lucila
    O'Neill, Edward A.
    Zimmer, Zachary
    Suryawanshi, Shailaja
    Engel, Samuel S.
    Lai, Eseng
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2017, 71 (06)
  • [18] Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects
    Krishna, Rajesh
    Addy, Carol
    Tatosian, Daniel
    Glasgow, Xiaoli S.
    Gendrano, Isaias Noel, III
    Robberechts, Martine
    Haazen, Wouter
    de Hoon, J. N.
    Depre, Marleen
    Martucci, Ashley
    Peng, Joanna Z.
    Johnson-Levonas, Amy O.
    Wagner, John A.
    Stoch, S. Aubrey
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (12): : 1528 - 1537
  • [19] Evolution of a Manufacturing Route to Omarigliptin, A Long-Acting DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
    Chung, John Y. L.
    Scott, Jeremy P.
    Anderson, Camille
    Bishop, Brian
    Bremeyer, Nadine
    Cao, Yang
    Chen, Qmghao
    Dunn, Robert
    Kassim, Amude
    Lieberman, David
    Moment, Aaron J.
    Sheen, Faye
    Zacuto, Michael
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2015, 19 (11) : 1760 - 1768
  • [20] PHARMACOKINETICS OF OMARIGLIPTIN (MK-3102), A ONCE-WEEKLY DIPEPTIDYL PEPTIDASE-IV (DPP-4) INHIBITOR, IN PATIENTS WITH RENAL IMPAIRMENT
    Tatosian, D. A.
    Glasgow, S.
    Caceres, M.
    Grenier, J.
    DeGroot, B.
    Ward, T.
    Johnson-Levonas, A.
    George, L.
    Lasseter, K. C.
    Marbury, T. C.
    Kauh, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S90 - S90
12345